FDA Reviews Achieve Life Sciences' Cytisinicline for Smoking Cessation

FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.